Search
Search
AAO: 2025
Jennifer Lim, MD
Show Description +
Dr. Lim highlights the latest phase 3 data for faricimab (Vabysmo, Genentech/Roche), 8 mg aflibercept (Eylea HD, Regeneron), and the port delivery system with ranibizumab (Susvimo, Genentech/Roche). She also touches on novel therapies in the pipeline.
Posted: 10/23/2025
Jennifer Lim, MD
Dr. Lim highlights the latest phase 3 data for faricimab (Vabysmo, Genentech/Roche), 8 mg aflibercept (Eylea HD, Regeneron), and the port delivery system with ranibizumab (Susvimo, Genentech/Roche). She also touches on novel therapies in the pipeline.
Posted: 10/23/2025
Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of AAO: 2025.
Please log in to leave a comment.